Search results for "breast neoplasms"

showing 10 items of 804 documents

Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer

2013

Abstract Background The human ERBB2 gene is frequently amplified in breast tumors, and its high expression is associated with poor prognosis. We previously reported a significant inverse correlation between Myc promoter-binding protein-1 (MBP-1) and ERBB2 expression in primary breast invasive ductal carcinoma (IDC). MBP-1 is a transcriptional repressor of the c-MYC gene that acts by binding to the P2 promoter; only one other direct target of MBP-1, the COX2 gene, has been identified so far. Methods To gain new insights into the functional relationship linking MBP-1 and ERBB2 in breast cancer, we have investigated the effects of MBP-1 expression on endogenous ERBB2 transcript and protein lev…

Cancer ResearchMBP-1/EnolaseReceptor ErbB-2Breast NeoplasmsHistone Deacetylase 1BiologyERBB geneBreast cancerTranscriptional regulationTranscription (biology)Histone DeacetylaseBreast CancermedicineTranscriptional regulationBiomarkers TumorTumor Cells CulturedGeneticsHumansMBP-1ERBB2Promoter Regions Geneticskin and connective tissue diseasesGeneReporter geneCarcinoma Ductal BreastCancerTransfectionGenes erbB-2medicine.diseaseImmunohistochemistryHDAC1Neoplasm ProteinsDNA-Binding ProteinsGene Expression Regulation NeoplasticSettore BIO/18 - GeneticaOncologyCancer researchChromatin immunoprecipitationResearch ArticleBMC Cancer
researchProduct

Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer

2010

El pdf del artículo es la versión de autor.-- et al.

Cancer ResearchMicroarrayGene DosageGene ExpressionEstrogen receptorBreast NeoplasmsGene dosageMiceBreast cancerOriginal ReportsAnimalsHumansMedicineGenetic Predisposition to DiseaseCopy-number variationskin and connective tissue diseasesSequence Deletionbusiness.industryCancerPeriod Circadian ProteinsPrognosismedicine.diseaseSurvival AnalysisDisease Models AnimalReceptors EstrogenOncologyChromosomes Human Pair 1Cancer researchFemaleBreast diseaseNeoplasm Recurrence LocalbusinessTamoxifenmedicine.drugJournal of Clinical Oncology
researchProduct

Breast cancer genome-wide association studies: there is strength in numbers.

2012

Breast cancer (BC) is a heterogeneous disease that exhibits familial aggregation. Family linkage studies have identified high-penetrance genes, BRCA1, BRCA2, PTEN and TP53, that are responsible for inherited BC syndromes. Moreover, a combination of family-based and population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP and PALB2, are associated with moderate risk. Therefore, all of these known genes account for only 25% of the familial aggregation cases. Recently, genome wide association studies (GWAS) in BC revealed single nucleotide polymorphisms (SNPs) in five novel genes associated to susceptibility: TNRC9, FGFR2, MAP3K1, H19 and lymphocyte-spe…

Cancer ResearchMultifactorial InheritanceSettore MED/06 - Oncologia MedicaPALB2PopulationMAP Kinase Kinase Kinase 1Single-nucleotide polymorphismGenome-wide association studyBreast NeoplasmsBiologyPolymorphism Single NucleotideGenetic linkageGeneticsSNPHumansGenetic Predisposition to DiseaseReceptor Fibroblast Growth Factor Type 2educationMolecular BiologyGeneCHEK2Geneticsbreast cancer GWASeducation.field_of_studyMicrofilament ProteinsHigh Mobility Group ProteinsCancer researchTrans-ActivatorsFemaleApoptosis Regulatory ProteinsReceptors ProgesteroneGenome-Wide Association StudyOncogene
researchProduct

Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.

2013

Notch is a family of transmembrane receptors whose activation through proteolytic cleavage by γ-secretase targets genes which participate in cell development, differentiation and tumorigenesis. Notch signaling is constitutively activated in various cancers, including breast cancer and its upregulation is usually related with poor clinical outcomes. Therefore, targeting Notch signaling with γ-secretase inhibitors (GSIs) is considered a promising strategy for cancer treatment. We report that the γ-secretase inhibitor-I (GSI-I) sensitizes human breast cancer cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The antiproliferative GSI-I/TRAIL synergi…

Cancer ResearchNotch signaling pathwayApoptosisBreast NeoplasmsBiologymedicine.disease_causeTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationGenes junSettore BIO/10 - BiochimicaSurvivinmedicineHumansTranscription factorReceptors NotchCell DifferentiationCell biologyGene Expression Regulation NeoplasticReceptors TNF-Related Apoptosis-Inducing LigandOncologyApoptosisCancer cellMCF-7 CellsFemalenotch signaling γ-secretase inhibitor-I/TRAIL combined treatment apoptosis breast cancer cells AP-1Signal transductionAmyloid Precursor Protein SecretasesCarcinogenesisSignal TransductionInternational journal of oncology
researchProduct

Metalloproteinase and TIMP expression by the human breast carcinoma cell line 8701-BC.

1993

It is widely accepted that collagenolytic enzymes are required to facilitate the invasion and spread of tumour cells into host tissues. Immunohistochemical, zymographic and PCR analyses have produced evidence that the recently established human mammary carcinoma cell line, 8701-BC, expresses several metalloproteinases (MMP-1, -2, -9 and -10) and their tissue inhibitors (TIMP-1 and -2). Application of these different techniques has led to several observations, both complementary and dissimilar. Whereas PCR analysis showed that mRNA was detected for each of the proteins, the immunolocalization study demonstrated that MMP-1, MMP-2, MMP-9 and TIMP-1 production was restricted to only a proportio…

Cancer ResearchPathologymedicine.medical_specialtyCell divisionMatrix metalloproteinase inhibitorCellFluorescent Antibody TechniqueBreast NeoplasmsMatrix metalloproteinaseBiologyMatrix Metalloproteinase InhibitorsPolymerase Chain ReactionmedicineTumor Cells CulturedHumansGlycoproteinsMatrigelMetalloproteinaseChemotaxisCarcinomaMetalloendopeptidasesTissue Inhibitor of MetalloproteinasesMolecular biologymedicine.anatomical_structureOncologyCell cultureInterstitial collagenaseElectrophoresis Polyacrylamide GelCell DivisionInternational journal of cancer
researchProduct

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

2009

Abstract Tumors may be initiated and maintained by a cellular subcomponent that displays stem cell properties. We have used the expression of aldehyde dehydrogenase as assessed by the ALDEFLUOR assay to isolate and characterize cancer stem cell (CSC) populations in 33 cell lines derived from normal and malignant mammary tissue. Twenty-three of the 33 cell lines contained an ALDEFLUOR-positive population that displayed stem cell properties in vitro and in NOD/SCID xenografts. Gene expression profiling identified a 413-gene CSC profile that included genes known to play a role in stem cell function, as well as genes such as CXCR1/IL-8RA not previously known to play such a role. Recombinant int…

Cancer ResearchPathologymedicine.medical_specialtyCellular differentiation[SDV.CAN]Life Sciences [q-bio]/CancerBreast Neoplasms[SDV.BC]Life Sciences [q-bio]/Cellular BiologyMice SCIDBiologyStem cell markerArticleCell LineReceptors Interleukin-8AMetastasisMice03 medical and health sciences0302 clinical medicineMice Inbred NODCancer stem cellCell Line TumorBiomarkers TumormedicineAnimalsHomeostasisHumansBreastRNA MessengerRNA NeoplasmNeoplasm MetastasisOligonucleotide Array Sequence Analysis030304 developmental biologySettore MED/04 - Patologia Generale0303 health sciencesReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingStem CellsCancerAldehyde DehydrogenaseFlow Cytometrymedicine.disease3. Good healthOncologyCell culture030220 oncology & carcinogenesisCancer researchFemaleStem cellImmortalised cell lineAldefluor breast cancer cell
researchProduct

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells

2014

Triple negative breast cancer (TNBC) is a very aggressive subgroup of breast carcinoma, still lacking specific markers for an effective targeted therapy and with a poorer prognosis compared to other breast cancer subtypes. In this study we investigated the possibility that TNBC cells contribute to the establishment of tumor vascular network by the process known as vasculogenic mimicry, through endothelial cell differentiation. Vascular-like functional properties of breast cancer cell lines were investigated in vitro by tube formation assay and in vivo by confocal microscopy, immunofluorescence or immunohistochemistry on frozen tumor sections. TNBCs express endothelial markers and acquire th…

Cancer ResearchPathologymedicine.medical_specialtyPDGFRmedicine.medical_treatmentTriple Negative Breast NeoplasmsMice SCIDBiologyEndothelial cell differentiationTargeted therapyReceptor Platelet-Derived Growth Factor betachemistry.chemical_compoundBreast cancerCell Line TumorGeneticsmedicineAnimalsHumansVasculogenic mimicryBreastRNA Small InterferingReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesTriple-negative breast cancerResearch ArticlesNeovascularization PathologicFGFREndothelial CellsCell DifferentiationGeneral MedicineTriple Negative Breast Neoplasmsmedicine.diseaseImmunohistochemistryVascular endothelial growth factorOncologychemistryVasculogenic mimicryCancer researchMolecular MedicineTNBC; Vasculogenic mimicry; PDGFR; FGFRTriple-Negative Breast CarcinomaFemaleRNA InterferenceTNBC
researchProduct

Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

2009

Abstract Purpose: To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer. Experimental Design: CSCs were isolated from SUM149 and MARY-X, an IBC cell line and primary xenograft, by virtue of increased aldehyde dehydrogenase (ALDH) activity as assessed by the ALDEFLUOR assay. Invasion and metastasis of CSC populations were assessed by in vitro and mouse xenograft assays. Expression of ALDH1 was determined on a retrospective series of 109 IBC patients and this was correlated with histoclinical data. All statistical tests were two sided. Log-rank …

Cancer ResearchPathologymedicine.medical_specialtyRetinal dehydrogenaseALDHBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerMice SCID[SDV.BC]Life Sciences [q-bio]/Cellular BiologyInflammatory breast cancerAldehyde Dehydrogenase 1 FamilyArticleMetastasisMice03 medical and health sciences0302 clinical medicineBreast cancerMice Inbred NODCancer stem cellCell Line TumorBiomarkers TumorAnimalsHumansMedicineNeoplasm Metastasisskin and connective tissue diseases030304 developmental biologyInflammationSettore MED/04 - Patologia Generale0303 health sciencesbusiness.industryRetinal DehydrogenaseCancerAldehyde Dehydrogenasemedicine.disease3. Good healthIsoenzymesTreatment OutcomeOncology030220 oncology & carcinogenesisbreast tumor cancer stem cellsNeoplastic Stem CellsCancer researchFemaleBreast diseaseStem cellbusinessNeoplasm Transplantation
researchProduct

A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast

1989

A cell line, designated 8701-BC, was established in culture from tissue fragments of primary ductal infiltrating carcinoma of human breast. The cell cultures after the sixth passage were devoid of contaminating fibroblasts as judged by the positive staining of all cells with the specific epithelial cell markers carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and cytokeratin 8. The epithelial nature of these cells was confirmed by ultrastructural analyses which demonstrated the retention of specific structural properties characteristic of the original tumour. The cells possessed an abnormal karyotype with 55-60 chromosomes per cell with numerous rearrangements. They do not e…

Cancer ResearchPathologymedicine.medical_specialtyStromal cellbiologyTissue Polypeptide AntigenCellBreast NeoplasmsMolecular biologyEpitheliumCell LineCarcinoma Intraductal Noninfiltratingmedicine.anatomical_structureCarcinoembryonic antigenOncologyCell cultureKaryotypingTumor Cells Culturedmedicinebiology.proteinKeratin 8HumansNeoplastic cellResearch ArticleBritish Journal of Cancer
researchProduct

Underuse of long-term routine hospital follow-up care in patients with a history of breast cancer?

2011

Abstract Background After primary treatment for breast cancer, patients are recommended to use hospital follow-up care routinely. Long-term data on the utilization of this follow-up care are relatively rare. Methods Information regarding the utilization of routine hospital follow-up care was retrieved from hospital documents of 662 patients treated for breast cancer. Utilization of hospital follow-up care was defined as the use of follow-up care according to the guidelines in that period of time. Determinants of hospital follow up care were evaluated with multivariate analysis by generalized estimating equations (GEE). Results The median follow-up time was 9.0 (0.3-18.1) years. At fifth and…

Cancer ResearchPediatricsMultivariate analysisAftercareComorbidityGUIDELINESGeelaw.inventionCohort StudiesRandomized controlled triallawNetherlandsAged 80 and overSURVIVORSmedicine.diagnostic_testBreast neoplasmFollow-upNeoplasms Second PrimaryMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyUtilizationOncologyPractice Guidelines as TopicRECURRENCESHormonal therapyFemaleGuideline AdherenceHEALTHResearch ArticleCohort studyMammographyAdultmedicine.medical_specialtyOutpatient Clinics HospitalAntineoplastic Agents HormonalMatched-Pair AnalysisBreast Neoplasmslcsh:RC254-282Breast cancerGeneticsmedicineHumansMammographyMETAANALYSISAgedbusiness.industryPatient Acceptance of Health Caremedicine.diseaseComorbidityTRENDSRANDOMIZED-TRIALHealth Care SurveysPhysical therapyPatient ComplianceUPDATESURVEILLANCE MAMMOGRAPHYbusinessFollow-Up Studies
researchProduct